XML 52 R36.htm IDEA: XBRL DOCUMENT v3.25.0.1
Stock-Based Compensation (Tables)
12 Months Ended
Dec. 31, 2024
Stock-Based Compensation  
Schedule of stock option activity

    

    

Weighted

    

Weighted

Average

Average

Exercise

Remaining

Price

Contractual

Shares

Per Share

Term (In Years)

Options outstanding at December 31, 2023

6,378,924

$

29.69

7.5

Granted

1,959,320

$

36.22

Exercised

(679,985)

$

12.98

Canceled

(118,150)

$

120.67

Options outstanding at December 31, 2024

7,540,109

$

31.47

7.5

Options vested and expected to vest at December 31, 2024

7,416,025

$

31.41

7.4

Options exercisable at December 31, 2024

3,980,565

$

29.17

6.3

Shares available for grant under the Celldex Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (as amended, effective as of June 13, 2024) at December 31, 2024

2,372,333

Schedule of stock-based compensation expense

    

2024

    

2023

    

2022

(In thousands)

Research and development

$

17,442

$

11,948

$

8,082

General and administrative

16,800

11,942

7,529

Total stock-based compensation expense

$

34,242

$

23,890

$

15,611

Schedule of assumptions used for the fair value of employee stock options granted

    

2024

    

2023

    

2022

Expected stock price volatility

82 -93%

92%

90 - 97%

Expected option term

6.0 Years

6.0 Years

6.0 Years

Risk-free interest rate

3.5 - 4.5%

3.5 - 4.7%

1.7 - 4.2%

Expected dividend yield

None

None

None